Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6861313,concentration,"An initial pharmacokinetic evaluation allowed design of a series of loading and maintenance infusions that produced plasma concentrations similar to those seen during encainide therapy in man (concentration after first maintenance dose, 149 +/- 27 ng/ml [+/- SE] and after second maintenance dose, 230 +/- 45 ng/ml).",Electrophysiologic actions of O-demethyl encainide: an active metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861313/),[ng] / [ml],149,3659,DB01228,Encainide
,6861313,concentration,"An initial pharmacokinetic evaluation allowed design of a series of loading and maintenance infusions that produced plasma concentrations similar to those seen during encainide therapy in man (concentration after first maintenance dose, 149 +/- 27 ng/ml [+/- SE] and after second maintenance dose, 230 +/- 45 ng/ml).",Electrophysiologic actions of O-demethyl encainide: an active metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861313/),[ng] / [ml],230,3660,DB01228,Encainide
,3081292,elimination t1/2,Extensive metabolizers of debrisoquin had a mean (+/- SD) encainide elimination t1/2 of 1.19 +/- 0.98 hours (range 0.25 to 3.4 hours).,Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081292/),h,1.19,18449,DB01228,Encainide
,3081292,t1/2,Poor metabolizers of debrisoquin (two normal subjects and three family members) had a mean t1/2 of 13.2 +/- 0.73 hours (range 7.8 to 22.4 hours).,Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081292/),h,13.2,18450,DB01228,Encainide
,2123007,steady-state,"Plasma concentration data demonstrated that although encainide metabolism to ODE was partially impaired by quinidine, subsequent 3-methoxy-O-desmethyl encainide formation from ODE was virtually completely inhibited; thus steady-state plasma ODE remained unchanged whereas plasma encainide increased 10-fold (21 +/- 30 to 240 +/- 118 ng/ml; P less than .05).",Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123007/),[ng] / [ml],21,23260,DB01228,Encainide
,2123007,steady-state,"Plasma concentration data demonstrated that although encainide metabolism to ODE was partially impaired by quinidine, subsequent 3-methoxy-O-desmethyl encainide formation from ODE was virtually completely inhibited; thus steady-state plasma ODE remained unchanged whereas plasma encainide increased 10-fold (21 +/- 30 to 240 +/- 118 ng/ml; P less than .05).",Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2123007/),[ng] / [ml],240,23261,DB01228,Encainide
,2805262,elimination half-life,Serial plasma sampling after programmed electrical stimulation indicated a minimum MODE elimination half-life of 8.2 +/- 5.4 hours.,"Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2805262/),h,8.2,38944,DB01228,Encainide
,6767186,half-life,"Drug elimination was rapid (the half-life was 1.9 to 3.8 hours), but the margin between efficacy and side effects was sufficiently wide for therapy every six to 12 hours to be feasible in all 10 patients, with continuing outpatient treatment at six to 12 months.",Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6767186/),h,1.9 to 3.8,77626,DB01228,Encainide
,2510135,oral clearance,Diltiazem 90 mg every 8 hours for 5 days decreased the oral clearance of antipyrine from 2.34 to 1.86 L/hour (p less than 0.05) and increased half-life from 12.7 to 15.9 hours (p less than 0.05).,The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510135/),[l] / [h],2,84358,DB01228,Encainide
,2510135,half-life,Diltiazem 90 mg every 8 hours for 5 days decreased the oral clearance of antipyrine from 2.34 to 1.86 L/hour (p less than 0.05) and increased half-life from 12.7 to 15.9 hours (p less than 0.05).,The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510135/),h,12,84359,DB01228,Encainide
,6788400,bioavailability,"There was a marked intersubject variation in bioavailability (mean 42 +/- 24%, range 7.4-82%), clearance (13.2 +/- 5.6 ml/min/kg, range 3.75-22.1 ml/min/kg) and half-life (3.4 +/- 1.7 hours i.v., 2.5 +/- 0.8 hours oral).",Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6788400/),%,42,94689,DB01228,Encainide
,6788400,clearance,"There was a marked intersubject variation in bioavailability (mean 42 +/- 24%, range 7.4-82%), clearance (13.2 +/- 5.6 ml/min/kg, range 3.75-22.1 ml/min/kg) and half-life (3.4 +/- 1.7 hours i.v., 2.5 +/- 0.8 hours oral).",Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6788400/),[ml] / [kg·min],13.2,94690,DB01228,Encainide
,6788400,half-life,"There was a marked intersubject variation in bioavailability (mean 42 +/- 24%, range 7.4-82%), clearance (13.2 +/- 5.6 ml/min/kg, range 3.75-22.1 ml/min/kg) and half-life (3.4 +/- 1.7 hours i.v., 2.5 +/- 0.8 hours oral).",Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6788400/),h,3.4,94691,DB01228,Encainide
,6788400,half-life,"There was a marked intersubject variation in bioavailability (mean 42 +/- 24%, range 7.4-82%), clearance (13.2 +/- 5.6 ml/min/kg, range 3.75-22.1 ml/min/kg) and half-life (3.4 +/- 1.7 hours i.v., 2.5 +/- 0.8 hours oral).",Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6788400/),h,2.5,94692,DB01228,Encainide
,6788400,Minimal antiarrhythmic plasma concentration,"Minimal antiarrhythmic plasma concentration was higher (39 +/- 54 ng/ml, range 3.5-170 ng/ml) after i.v. dosing than after oral dosing (14 +/- 16 ng/ml, range 1.5-48 ng/ml), suggesting an active metabolite after oral dosing in many patients.",Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6788400/),[ng] / [ml],39,94693,DB01228,Encainide
,6788400,Minimal antiarrhythmic plasma concentration,"Minimal antiarrhythmic plasma concentration was higher (39 +/- 54 ng/ml, range 3.5-170 ng/ml) after i.v. dosing than after oral dosing (14 +/- 16 ng/ml, range 1.5-48 ng/ml), suggesting an active metabolite after oral dosing in many patients.",Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6788400/),[ng] / [ml],14,94694,DB01228,Encainide
,6788400,peak plasma concentrations,"Minimal side effects were seen despite high peak plasma concentrations (range 794-1556 ng/ml i.v., 36-495 ng/ml oral).",Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6788400/),[ng] / [ml],794-1556,94695,DB01228,Encainide
,6788400,peak plasma concentrations,"Minimal side effects were seen despite high peak plasma concentrations (range 794-1556 ng/ml i.v., 36-495 ng/ml oral).",Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6788400/),[ng] / [ml],36-495,94696,DB01228,Encainide
,6788400,ratio of toxic to therapeutic plasma concentration,The minimal ratio of toxic to therapeutic plasma concentration ranged from 4.3-326 (median 23) after oral dosing.,Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6788400/),,23,94697,DB01228,Encainide
,3123092,clearance,"ODE clearance was a function of metabolizer phenotype, with higher clearance (mean 914 ml/min; range 554 to 1,314) in EMs than in PMs (434, 298 ml/min); moreover, 3MODE was detected during ODE infusions in all seven EMs but in neither PM.","Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3123092/),[ml] / [min],914,115853,DB01228,Encainide
,3123092,clearance,"ODE clearance was a function of metabolizer phenotype, with higher clearance (mean 914 ml/min; range 554 to 1,314) in EMs than in PMs (434, 298 ml/min); moreover, 3MODE was detected during ODE infusions in all seven EMs but in neither PM.","Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3123092/),[ml] / [min],"434,",115854,DB01228,Encainide
,3123092,clearance,3MODE clearance was more uniform (mean 289 ml/min in EMs [range 180-410] vs 300 and 78 ml/min in the two PMs) and ODE was not detected in any subject during 3MODE infusion.,"Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3123092/),[ml] / [min],289,115855,DB01228,Encainide
,3123092,clearance,3MODE clearance was more uniform (mean 289 ml/min in EMs [range 180-410] vs 300 and 78 ml/min in the two PMs) and ODE was not detected in any subject during 3MODE infusion.,"Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3123092/),[ml] / [min],300,115856,DB01228,Encainide
,3123092,clearance,3MODE clearance was more uniform (mean 289 ml/min in EMs [range 180-410] vs 300 and 78 ml/min in the two PMs) and ODE was not detected in any subject during 3MODE infusion.,"Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3123092/),[ml] / [min],78,115857,DB01228,Encainide
,3092618,bioavailability,"This metabolism occurs in the liver, and encainide clearance is sufficiently high that a significant first-pass effect is seen during oral therapy (bioavailability 30 +/- 7%).",Disposition kinetics of encainide and metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),%,30,130234,DB01228,Encainide
,3092618,systemic clearance,"In this poor metabolizer subset, the systemic clearance of encainide is 10-fold lower than in extensive metabolizers (0.18 +/- .002 vs 1.9 +/- 0.2 liters/min), the first-pass effect is virtually absent (bioavailability 83% to 88%), plasma concentrations are higher and an antiarrhythmic effect may be seen at usual encainide doses.",Disposition kinetics of encainide and metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),[l] / [min],0.18,130235,DB01228,Encainide
,3092618,systemic clearance,"In this poor metabolizer subset, the systemic clearance of encainide is 10-fold lower than in extensive metabolizers (0.18 +/- .002 vs 1.9 +/- 0.2 liters/min), the first-pass effect is virtually absent (bioavailability 83% to 88%), plasma concentrations are higher and an antiarrhythmic effect may be seen at usual encainide doses.",Disposition kinetics of encainide and metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),[l] / [min],1.9,130236,DB01228,Encainide
,3092618,bioavailability,"In this poor metabolizer subset, the systemic clearance of encainide is 10-fold lower than in extensive metabolizers (0.18 +/- .002 vs 1.9 +/- 0.2 liters/min), the first-pass effect is virtually absent (bioavailability 83% to 88%), plasma concentrations are higher and an antiarrhythmic effect may be seen at usual encainide doses.",Disposition kinetics of encainide and metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),%,83,130237,DB01228,Encainide
,3092618,bioavailability,"In this poor metabolizer subset, the systemic clearance of encainide is 10-fold lower than in extensive metabolizers (0.18 +/- .002 vs 1.9 +/- 0.2 liters/min), the first-pass effect is virtually absent (bioavailability 83% to 88%), plasma concentrations are higher and an antiarrhythmic effect may be seen at usual encainide doses.",Disposition kinetics of encainide and metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),%,88,130238,DB01228,Encainide
,3092618,Minimally effective plasma concentrations,"Minimally effective plasma concentrations appear to be 35 ng/ml (ODE), 100 ng/ml (3-MODE) and 300 ng/ml (encainide), making ODE one of the most potent sodium channel blockers yet used in man.",Disposition kinetics of encainide and metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),[ng] / [ml],35,130239,DB01228,Encainide
,3092618,Minimally effective plasma concentrations,"Minimally effective plasma concentrations appear to be 35 ng/ml (ODE), 100 ng/ml (3-MODE) and 300 ng/ml (encainide), making ODE one of the most potent sodium channel blockers yet used in man.",Disposition kinetics of encainide and metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),[ng] / [ml],100,130240,DB01228,Encainide
,3092618,Minimally effective plasma concentrations,"Minimally effective plasma concentrations appear to be 35 ng/ml (ODE), 100 ng/ml (3-MODE) and 300 ng/ml (encainide), making ODE one of the most potent sodium channel blockers yet used in man.",Disposition kinetics of encainide and metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),[ng] / [ml],300,130241,DB01228,Encainide
,3092618,elimination half-life,The elimination half-life of encainide is 2.3 +/- 0.3 hours in extensive metabolizer patients.,Disposition kinetics of encainide and metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),h,2.3,130242,DB01228,Encainide
,3092618,elimination,"Despite this rapid elimination, encainide can be administered every 8 to 12 hours in both extensive and poor metabolizer subsets; this is because of slowly eliminated metabolites in extensive metabolizers and slower elimination of encainide itself (11.3 +/- 0.3 hours) in poor metabolizers.",Disposition kinetics of encainide and metabolites. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092618/),h,11.3,130243,DB01228,Encainide
,2125833,oral bioavailability,Over 90% of patients are extensive metabolizers (EM) in whom the oral bioavailability of encainide is only 30% because of extensive first-pass metabolism.,Pharmacokinetics and metabolism of encainide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),%,30,156225,DB01228,Encainide
,2125833,elimination t1/2,"In EMs, elimination t1/2 is about 2.5 hours, with a systemic clearance of 1.8 l/min.",Pharmacokinetics and metabolism of encainide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),h,2.5,156226,DB01228,Encainide
,2125833,systemic clearance,"In EMs, elimination t1/2 is about 2.5 hours, with a systemic clearance of 1.8 l/min.",Pharmacokinetics and metabolism of encainide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[l] / [min],1.8,156227,DB01228,Encainide
,2125833,oral bioavailability,"The remaining patients (less than 10%) are poor metabolizers (PM), in whom the oral bioavailability is near 88% with an elimination t1/2 of 8-11 hours and a systemic clearance of 0.2 l/min.",Pharmacokinetics and metabolism of encainide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),%,88,156228,DB01228,Encainide
,2125833,elimination t1/2,"The remaining patients (less than 10%) are poor metabolizers (PM), in whom the oral bioavailability is near 88% with an elimination t1/2 of 8-11 hours and a systemic clearance of 0.2 l/min.",Pharmacokinetics and metabolism of encainide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),h,8-11,156229,DB01228,Encainide
,2125833,systemic clearance,"The remaining patients (less than 10%) are poor metabolizers (PM), in whom the oral bioavailability is near 88% with an elimination t1/2 of 8-11 hours and a systemic clearance of 0.2 l/min.",Pharmacokinetics and metabolism of encainide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[l] / [min],0.2,156230,DB01228,Encainide
,2125833,plasma protein binding,"The conversion to the N-desmethyl-encainide (NDE) metabolite seems to be similar in both metabolizer groups, and plasma protein binding of encainide of 70-78% is also similar.",Pharmacokinetics and metabolism of encainide. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),%,70-78,156231,DB01228,Encainide
,2125833,Minimally effective plasma concentrations,"Minimally effective plasma concentrations appear to be approximately 300 ng/ml of encainide, 35 ng/ml of ODE, and 100 ng/ml of 3-MODE.",Pharmacokinetics and metabolism of encainide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[ng] / [ml],300,156232,DB01228,Encainide
,2125833,Minimally effective plasma concentrations,"Minimally effective plasma concentrations appear to be approximately 300 ng/ml of encainide, 35 ng/ml of ODE, and 100 ng/ml of 3-MODE.",Pharmacokinetics and metabolism of encainide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[ng] / [ml],35,156233,DB01228,Encainide
,2125833,Minimally effective plasma concentrations,"Minimally effective plasma concentrations appear to be approximately 300 ng/ml of encainide, 35 ng/ml of ODE, and 100 ng/ml of 3-MODE.",Pharmacokinetics and metabolism of encainide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[ng] / [ml],100,156234,DB01228,Encainide
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB01228,Encainide
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB01228,Encainide
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB01228,Encainide
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB01228,Encainide
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB01228,Encainide
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB01228,Encainide
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB01228,Encainide
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB01228,Encainide
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB01228,Encainide
,6423808,oral bioavailability,"In the EM group, the oral bioavailability of encainide was only about 25 to 30% because of extensive presystemic (first-pass) metabolism, and no accumulation occurred after multiple oral dosing with 50 mg every 8 hr for 3 days, as the elimination half-life of the drug was about 2.5 hr.",Influence of genetic polymorphism on the metabolism and disposition of encainide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6423808/),%,25 to 30,177156,DB01228,Encainide
,6423808,elimination half-life,"In the EM group, the oral bioavailability of encainide was only about 25 to 30% because of extensive presystemic (first-pass) metabolism, and no accumulation occurred after multiple oral dosing with 50 mg every 8 hr for 3 days, as the elimination half-life of the drug was about 2.5 hr.",Influence of genetic polymorphism on the metabolism and disposition of encainide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6423808/),h,2.5,177157,DB01228,Encainide
,3131058,time required to achieve steady-state concentrations,"The time required to achieve steady-state concentrations of metabolites (in extensive metabolisers) and of encainide itself (in poor metabolisers) is similar (3 to 5 days); therefore, the dosage should be increased no more often than every 3 to 5 days.",Clinical pharmacokinetics of encainide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3131058/),d,3 to 5,198796,DB01228,Encainide
,2496225,systemic clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],935,251484,DB01228,Encainide
,2496225,systemic clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],190,251485,DB01228,Encainide
,2496225,nonrenal clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],782,251486,DB01228,Encainide
,2496225,nonrenal clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],95,251487,DB01228,Encainide
,2496225,elimination half-life,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),h,1.8,251488,DB01228,Encainide
,2496225,elimination half-life,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),h,7.7,251489,DB01228,Encainide
,2496225,fractional urinary recovery,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),%,17.5,251490,DB01228,Encainide
,2496225,fractional urinary recovery,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),%,47.4,251491,DB01228,Encainide
,3124082,half-life,"Encainide has a short half-life of 3 hours, but has 2 active metabolites with longer half-lives.","Encainide: its electrophysiologic and antiarrhythmic effects, pharmacokinetics, and safety. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3124082/),h,3,263270,DB01228,Encainide
